Why the study?
Does the combination of low-dose aspirin and dipyridamole reduce platelet uptake on atherosclerotic lesions in patients with ischaemic peripheral vascular disease?
Does the combination of low-dose aspirin and dipyridamole reduce platelet uptake on atherosclerotic lesions in patients with ischaemic peripheral vascular disease?
The combination of low-dose aspirin and dipyridamole significantly decreases platelet deposition on atherosclerotic lesions in patients with peripheral vascular disease, suggesting potential benefit in atherosclerosis treatment.
May support combined antiplatelet effects on lesions; hypothesis-generating and should not yet change practice in peripheral vascular disease.
Eighteen patients with ischaemic peripheral vascular disease were treated for a 5-week period with either 20 mg aspirin daily, 75 mg dipyridamole three times daily or a combination of these two treatments. Before and after 4 weeks' treatment autologous platelet labelling with 111In was carried out and sites of active vascular platelet uptake monitored, and platelet half-life measured. Neither aspirin nor dipyridamole alone had any effect on platelet uptake or on platelet half-life. The combination of aspirin and dipyridamole resulted in a significant decrease in platelet uptake and a nonsignificant trend towards prolongation of platelet half-life. These findings suggest that this combined therapy may be of benefit in the treatment of atherosclerosis in man.
No takes yet. Share an insight, caveat, or question.
Sinzinger et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: